Nitasha Sarswat to Amyloid Neuropathies, Familial
This is a "connection" page, showing publications Nitasha Sarswat has written about Amyloid Neuropathies, Familial.
Connection Strength
4.520
-
Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM. Future Cardiol. 2026 02; 22(2):119-133.
Score: 0.887
-
Impact of Tafamidis on Survival in a Real-World Community-Based Cohort. Curr Probl Cardiol. 2022 Dec; 47(12):101358.
Score: 0.697
-
Incremental prognostic value of cardiac magnetic resonance beyond biomarker staging in transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2026 Sep 01; 27(9):1603-1612.
Score: 0.231
-
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B. J Am Coll Cardiol. 2026 Sep 22; 88(12):1402-1412.
Score: 0.231
-
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial. J Am Heart Assoc. 2026 Oct 06; 15(19):e050566.
Score: 0.231
-
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026 05 01; 11(5):446-454.
Score: 0.225
-
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
Score: 0.225
-
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. JAMA Cardiol. 2026 01 01; 11(1):57-67.
Score: 0.220
-
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation. 2026 Jan 27; 153(4):214-225.
Score: 0.218
-
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging. 2025 Aug; 41(8):1487-1496.
Score: 0.212
-
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1911-1923.
Score: 0.211
-
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 04; 151(9):601-611.
Score: 0.204
-
99m Technetium-pyrophosphate bone scan: A potential biomarker for the burden of transthyretin amyloidosis in skeletal muscle: A preliminary study. Muscle Nerve. 2023 Feb; 67(2):111-116.
Score: 0.177
-
Progressive Multiple Mononeuropathy in a Patient With Familial Transthyretin Amyloidosis After Liver Transplantation. J Clin Neuromuscul Dis. 2022 Mar 01; 23(3):143-147.
Score: 0.169
-
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis. 2021 10 03; 16(1):411.
Score: 0.164
-
Clinical features of systemic amyloidosis: a scoping review. Blood Adv. 2026 Jul 28; 10(14):5097-5112.
Score: 0.057
-
Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection. Circ Cardiovasc Imaging. 2026 Jun; 19(6):e019610.
Score: 0.057
-
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. Eur Heart J. 2025 10 22; 46(40):4090-4101.
Score: 0.054
-
Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype. Curr Probl Cardiol. 2024 Sep; 49(9):102729.
Score: 0.050